104 related articles for article (PubMed ID: 18724534)
21. Protracted administration of weekly docetaxel in metastatic breast cancer.
Kuroi K; Bando H; Saji S; Toi M
Oncol Rep; 2003; 10(5):1479-84. PubMed ID: 12883727
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel for metastatic breast cancer: two consecutive phase II trials.
Campora E; Colloca G; Ratti R; Addamo G; Coccorullo Z; Venturino A; Guarneri D
Anticancer Res; 2008; 28(6B):3993-5. PubMed ID: 19192662
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
24. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Meluch AA; Spigel DR; Barton J; Simons L; Meng C; Gould B; Greco FA
Clin Genitourin Cancer; 2007 Mar; 5(4):278-83. PubMed ID: 17553208
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
Pearl ML; Johnston CM; McMeekin DS
Gynecol Obstet Invest; 2007; 64(4):193-8. PubMed ID: 17664880
[TBL] [Abstract][Full Text] [Related]
26. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
[TBL] [Abstract][Full Text] [Related]
27. Taxanes in elderly breast cancer patients.
Wildiers H; Paridaens R
Cancer Treat Rev; 2004 Jun; 30(4):333-42. PubMed ID: 15145508
[TBL] [Abstract][Full Text] [Related]
28. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients.
Willey CD; Murphy BA; Netterville JL; Burkey BB; Shyr Y; Shakhtour B; Kish B; Raben D; Chen C; Song JI; Kane MA; Cmelak AJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1323-31. PubMed ID: 17289289
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01.
Tinker AV; Gebski V; Fitzharris B; Buck M; Stuart-Harris R; Beale P; Goldrick A; Rischin D
Gynecol Oncol; 2007 Mar; 104(3):647-53. PubMed ID: 17079006
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer.
Alvarez EA; Wolfson AH; Pearson JM; Crisp MP; Mendez LE; Lambrou NC; Lucci JA
Gynecol Oncol; 2009 May; 113(2):195-9. PubMed ID: 19251309
[TBL] [Abstract][Full Text] [Related]
32. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
Amadori D; Milandri C; Comella G; Saracchini S; Salvagni S; Barone C; Bordonaro R; Gebbia V; Barbato A; Serra P; Gattuso D; Nanni O; Baconnet B; Gasparini G
Eur J Cancer; 2011 Sep; 47(14):2091-8. PubMed ID: 21665463
[TBL] [Abstract][Full Text] [Related]
33. A deferred dilemma.
Srinivas R; Agarwal R; Aggarwal AN
Am J Med; 2007 Jul; 120(7):594-7. PubMed ID: 17602932
[No Abstract] [Full Text] [Related]
34. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Mrozek E; Ramaswamy B; Young D; Rhoades CA; Kendra K; Allen J; Moore T; Hauger M; Watson H; Merriman N; Nadella P; Villalona-Calero M; Shapiro CL
Clin Breast Cancer; 2006 Jun; 7(2):141-5. PubMed ID: 16800973
[TBL] [Abstract][Full Text] [Related]
35. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
36. A phase I-II study of bi-weekly docetaxel combined with radiation therapy for patients with cancer of the larynx/hypopharynx.
Yoshida T; Tokashiki R; Itoh H; Nakamura K; Hiramatsu H; Tsukahara K; Shimizu S; Takada D; Okamoto I; Abe K; Suzuki M
Jpn J Clin Oncol; 2007 Sep; 37(9):641-6. PubMed ID: 17940076
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous reaction associated with weekly docetaxel administration.
Chew L; Chuen VS
J Oncol Pharm Pract; 2009 Mar; 15(1):29-34. PubMed ID: 18753180
[TBL] [Abstract][Full Text] [Related]
38. Diffuse psoriasis induced by docetaxel in a 62-year-old woman with breast carcinoma.
Mapelli ET; Gualandri L; Menni S; Cerri A
G Ital Dermatol Venereol; 2016 Jun; 151(3):309-10. PubMed ID: 27176084
[No Abstract] [Full Text] [Related]
39. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
[TBL] [Abstract][Full Text] [Related]
40. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Specenier P; Rasschaert M; Vroman P; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
Am J Clin Oncol; 2011 Oct; 34(5):472-7. PubMed ID: 20938321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]